Drug intelligence / Profile preview

JNJ-17299425

Development stage: Discontinued
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Intravenous

Overview

JNJ-17299425 is an investigational small molecule drug that was developed by Johnson & Johnson for the treatment of nervous system diseases, specifically as an intravenous agent for traumatic brain injury. The drug's development has been discontinued and it did not reach the market. Its precise mechanism of action has not been widely published, but it was under investigation in the context of central nervous system disorders[2][3].

Targets

AQP4 (Aquaporin-4)

Beyond the preview

Go deeper on JNJ-17299425.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-17299425.

Explore the full profile